-
Featured News /
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
-
Statement /
-
Story /Novartis researchers aim to preserve kidney function – and quality of life – for patients.
-
Story /New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.
-
Story /Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.
-
Story /The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.
-
Featured News /
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. -
Story /By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Featured News /
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
-
Story /Novartis is investing in a novel type of medicine to reduce the risk of heart disease.